Tuteja, Ashok K.
Talley, Nicholas J.
Stoddard, Gregory J.
Verne, G. Nicholas
Funding for this research was provided by:
Department of Veterans Affairs (1I01CX001477-01)
National Institute of Diabetes and Digestive and Kidney Diseases (DK099052)
Department of Defense (W81XWH-10-1-0593, W81XWH-15-1-0636)
Article History
Received: 29 May 2018
Accepted: 17 October 2018
First Online: 28 October 2018
Compliance with ethical standards
:
: AKT has received funding from Shire and Synergy Pharmaceuticals. NJT Grant/Research Support: Rome Foundation; Abbott Pharmaceuticals; Datapharm; Pfizer; Salix [Irritable bowel syndrome]; Prometheus Laboratories Inc [Irritable bowel syndrome (IBS Diagnostic)]; Janssen [Constipation]. Consultant/Advisory Boards: Adelphi Values [Functional dyspepsia (patient-reported outcome measures)]; (Budesonide)]; GI therapies [Chronic constipation (Rhythm IC)]; Sax Institute; Allergens PLC; Napo Pharmaceutical; Outpost Medicine; Samsung Bioepis; Yuhan [IBS]; Synergy [IBS]; Theravance [Gastroparesis]; Patent Holder: Biomarkers of irritable bowel syndrome [Irritable bowel syndrome] Licensing Questionnaires [Mayo Clinic Talley Bowel Disease Questionnaire—Mayo Dysphagia Questionnaire]; Nestec European Patent [Application No. 12735358.9]; Singapore “Provisional” Patent [NTU Ref: TD/129/17 “Microbiota Modulation Of BDNF Tissue Repair Pathway”].